Xraphconn

Xraphconn® is the Mutian protocol supply for cats facing feline infectious peritonitis (FIP) — historically one of the most difficult conditions in feline medicine. It is intended for the wet (effusive), dry (non-effusive), and neurological and ocular presentations of FIP, giving owners and their attending veterinarians a single product family to work with across the spectrum of the condition.

Xraphconn® is administered as part of a structured observational protocol. The standard course runs for 84 days (12 weeks) of once-daily dosing, taken orally on an empty stomach where tolerated; an equivalent injection course is available for cats that cannot reliably take tablets. For ocular or neurological involvement the protocol is extended to roughly 112 days (16 weeks), and the attending veterinarian may adjust the daily amount upward for these more severe presentations. Because dosing is weight-based and presentation-dependent, owners are asked to share the most severe symptoms the cat has ever shown — not only its current state — so the course is not under-scaled.

Xraphconn® is supplied as oral tablets in 12.5 mg, 25 mg, and 50 mg strengths (14 tablets per box) and as Xraphconn® II injection (120 mg / 6 ml per vial, also offered in 3-vial and 6-vial packs). The oral strengths map to body weight at one tablet per day: the 12.5 mg tablet covers 1 kg, the 25 mg tablet covers 2 kg, and the 50 mg tablet covers 4 kg. The strength and pack are chosen to suit the cat's body weight and the length of the planned course; the injection amount is set by the attending veterinarian according to the presentation.

Administration notes from the source research: give the tablets on an empty stomach with water — at least one hour before, or two hours after, meals, milk, or other dairy products. Do not give antacids, sucralfate, or multivitamins and supplements containing iron, zinc, magnesium, or aluminium within two hours before or after Xraphconn®. Consult your veterinarian for help in the diagnosis, treatment, and control of FIP.

Technical details: active ingredient MT0901 (Patent US10988503B1). Manufactured under GMP-certified conditions. Xraphconn® is an experimental research compound supplied for use within observational FIP protocols and is not represented as a guaranteed cure; outcomes are tracked as observational response over the course of the protocol.